<DOC>
	<DOCNO>NCT02711605</DOCNO>
	<brief_summary>Male volunteer suffer Pseudogynecomastia seek noninvasive breast fat reduction enrol two arm receive three biweekly UltraShape treatment .</brief_summary>
	<brief_title>UltraShape Device Non-Invasive Fat Reduction Male Breast ( Pseudogynecomastia )</brief_title>
	<detailed_description>Up 40 adult male volunteer , suffer Pseudogynecomastia , seek noninvasive breast fat reduction enrol three investigational site . Eligible subject divide one two treatment arm : Arm 1 : Subjects treat one side breast , opposite side serve control - Up 20 subject ; Arm 2 : Subjects treat side breast - Up 20 subject . Subjects receive 3 bi-weekly treatment ( 2-week interval ) UltraShape device . Subjects return 3 follow-up visit post last treatment ( Tx.3 ) : four week follow-up ( 4wk FU ) , eight week follow-up ( 8wk FU ) 12 week follow-up ( 12wk FU ) total expect study duration 16 week .</detailed_description>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Gynecomastia</mesh_term>
	<criteria>1 . Signed informed consent participate study 2 . Male subject , 18 70 year age time enrollment 3 . BMI interval : BMI ≥ 22 ≤30 ( normal overweight , obese ) 4 . Fat thickness least 1.5 cm treat area ( breast ) measure calibrate caliper . 5 . Subject clearly visible , palpable , excess fatty tissue breast area , minimal fibrous tissue . 6 . Subject agree maintain weight ( i.e. , within 3 % weight change ) make major change diet lifestyle course study . 7 . General good health confirm medical history skin examination treat area . 8 . Willing follow treatment followup schedule posttreatment care instruction . 9 . Willing photograph image take treated area use , deidentified evaluation , publication presentation . 1 . History hypertension , ischemic heart disease , valvular heart disease , congestive heart failure , pacemaker/defibrillator . 2 . Known hyperlipidemia , diabetes mellitus , hepatitis , liver disease , HIV positive status , blood coagulopathy excessive bleeding , autoimmune connective tissue disease . 3 . Having undergoing form treatment active cancer , history skin cancer cancer area treat , include presence malignant pre‐malignant pigment lesion . 4 . Having active electrical implant anywhere body , pacemaker internal defibrillator . 5 . Having permanent implant treat area , metal plate inject chemical substance silicone . 6 . Having undergone surgery treat area within 12 month treatment study , include liposuction . 7 . Previous body contour procedure treatment area within 12 month . 8 . History skin disease treatment area , know tendency form keloid poor wound heal . 9 . Suffering significant skin condition treat area inflammatory skin condition , include , limited , open laceration abrasion active cold sore herpes sore prior treatment ( duration resolution per Investigator 's discretion ) treatment course . 10 . Skin lesion treatment area simple nevi physical examination ( e.g. , atypical nevus , tattoo , abrasion ) include depressed scar treatment area . 11 . Very poor skin quality ( i.e. , severe laxity ) accord investigator decision . 12 . Obesity ( BMI &gt; 30 ) . 13 . Unstable weight within last 6 month ( i.e. , 3 % weight change prior six month ) . 14 . Inability comply circumference measurement procedure ( e.g. , inability hold breath require duration ) . 15 . Fat thickness lower 2.5 cm strapping treat area . 16 . Participation another clinical study involve anatomical area within last 6 month ( 30 day case different anatomical area treat previous trial/s ) . 17 . As per Investigator 's discretion , physical mental condition might make unsafe subject participate study . 18 . Personal history previous breast malignancy . 19 . Subject take medication could cause abnormal breast enlargement include limited : digoxin , furosemide , gonadotropin , clomiphene , phenytoin , exogenous testosterone , ketoconazole , metronidazole , alkylating agent , cisplatin , spironolactone , cimetidine , flutamide , finasteride , etomidate , isonicotinic acid hydrazide , methyldopa , busulfan , tricyclic antidepressant , diazepam , penicillamine , omeprazole , phenothiazine , calcium channel blocker , angiotensinconverting enzyme ( ACE ) inhibitor . 20 . Subject history follow medical condition : Klinefelter syndrome , Congenital anorchia , Testicular trauma , Testicular torsion , Viral orchitis , Kallmann syndrome , Pituitary tumor , Malignancies increase serum level hCG ( eg , large cell lung cancer , gastric carcinoma , renal cell carcinoma , hepatoma ) , Renal failure , Hyperthyroidism , Malnutrition , Androgen insensitivity syndrome , Fivealphareductase deficiency syndrome .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>ultrasound</keyword>
	<keyword>fat</keyword>
</DOC>